Real-world data analysis of the risk of Fournier’s gangrene in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i)

The present study found a significantly lower risk of FG in patients using SGLT2i in comparison with subjects not using SGLT2i. Due to specific limitations that come alongside with the applied study design, this result needs to be interpreted most cautiously. As the cohorts were matched for the frequency of diabetes mellitus (68.9% of the cohorts I and II) this risk factor for FG might have been mitigated among the individuals in cohort I due to the use of SGLT2i, which may in turn explain the abovementioned finding.